Pap Test – With or Without Vaginal Smear? by Valerija Miličić-Juhas et al.
Coll. Antropol. 34 (2010) 1: 69–74
Original scientific paper
Pap Test – With or Without Vaginal Smear?
Valerija Mili~i}-Juhas1,4, Marija Peri}1, Marija Pajtler1,4, Ivana Prvulovi}2 and Darko ^ur`ik3,4
1 Department of Clinical Cytology, University Hospital Center Osijek, Osijek, Croatia
2 Department of Clinical Cytology, General Hospital »Dr. J. Ben~evi}«, Sl. Brod, Croatia
3 Clinic of Obstetrics and Gynecology, University Hospital Center Osijek, Osijek, Croatia
4 University of Osijek, School of Medicine, Osijek, Croatia
A B S T R A C T
The aim of this study was to evaluate medical and economic justification of vaginal smears as a part of primary
screening for cervical carcinoma and its precursors. Study included 245.048 participants whose VCE (vaginal, cervical,
endocervical) smears were examined at Department of clinical cytology of University Hospital Center Osijek from 2003
till 2008. There were 12.639 (5.2%) abnormal findings, and they were divided into three groups: abnormal cells found
only in vaginal smear (V), abnormal cells found in vaginal and in at least one other smear (V+) and abnormal cells not
found in vaginal smear (C/E). These three groups were analysed in respect to cytological differential diagnosis and age
of participants. It was estimated how many women could be additionally included in the screening, if vaginal smear
would be included in the Pap test only after 50 years of age. In 6.9% of cytologically diagnosed lesions abnormal cells
were found exclusively in vaginal smears (0.35% of all findings). As for squamous cell lesions, 91.2% were mild lesions
(ASC and LSIL). Invasive squamous cell carcinoma was not diagnosed exclusively by vaginal smear in either woman
under 50 years of age, while in women over 50 years of age it was diagnosed in 2.3% of cases. Exclusively by vaginal
smear was diagnosed 3.9% of all AGC and 6.3% of adenocarcinoma, while in 85.0% of glandular epithelium lesions ab-
normal cells were not found in vaginal smears. Two thirds of adenocarcinoma diagnosed exclusively by vaginal smears
were endometrial adenocarcinoma, but that is only 10.3% of all endometrial carcinoma diagnosed by Pap test. Obtained
results show that taking of vaginal smears along with cervical and endocervical smears as a part of primary screening
for cervical carcinoma and its precursors in women under 50 years of age is not justifiable, since vaginal smear only has
a role in detection of endometrial carcinoma that are extremely rare in younger age groups. If vaginal smear would be
taken only in women over 50 years of age, additional 37.7% of women under 50, or 25.1% women over 50 years of age
could be included in the screening.
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Introduction
In vaginal smear Papanicolaou accidentally discov-
ered cells of cervical carcinoma and established new diag-
nostic method for detection of cervical carcinoma in
early, asymptomatic and curable stage1–3, and it is after
discovery and publication of this revolutionary under-
standing that vaginal smear became accepted as a
screening method for detection of premalignant and ma-
lignant changes in asymptomatic women. However, al-
ready in the first years of application of this method, it
was determined that samples obtained directly from cer-
vix using wooden spatula4 were more efficient and easier
to analyse than vaginal smears5, and later endocervical
canal sample was included in routine practice6. Beside
this historical significance, vaginal smear is valuable for
hormone status evaluation and detection of infections,
and in peri- and postmenopausal women for identifica-
tion of carcinoma cells from endometrium, tubes, ovaries
and cervix, incidence of which is significantly increasing
after 50 years of age.
Experience shows that vaginal smear analysis is time-
-consuming because this is a part of smear with the most
prominent degenerative changes of the cells and with the
highest number of inflammatory cells and microorgan-
isms. In contrast, it contains relatively small number of
cervical cells, among which is hard to find early preinva-
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sive lesions. Since more than 90% of neoplastic changes
of cervix develop in transformation zone7, sample taken
directly from cervix contains numerous abnormal cells,
including those located deeper that do not desquamate
spontaneously. Current practice is that LBC Pap test
contains only cervical and endocervical sample taken in
one act or separately with two different instruments.
Conventional Pap test has been conducted in Croatia
from the middle of the last century, and it includes sam-
ples taken from posterior fornix of vagina (vaginal), from
ectocervix (cervical) and from endocervical canal (endo-
cervical smear). However, large number of Pap tests with
insufficient number of educated cytotechnologists justi-
fies idea of possible exclusion of vaginal sample.
The aim of this study was to evaluate medical and eco-
nomic justifiability of vaginal smear as a part of primary
screening.
Materials and Methods
The study included 245.048 participants whose VCE
(vaginal, cervical and endocervical) smears were exam-
ined as a part of primary screening at Department for
clinical cytology of University Hospital Center Osijek
from 2003 till 2008. Vaginal and cervical samples were
taken using wooden spatula4, while endocervical samples
were taken using cotton swab or a brush, and were all
smeared on to one slide. Smears were examined by four
cytotechnologists, which daily examine on average 45
VCE smears smeared onto one slide. Results were classi-
fied in concordance with Croatian modification of Be-
thesda 2001 classification8,9, but in data processing diag-
noses dysplasia media, dysplasia gravis, carcinoma in
situ and carcinoma in situ with possible initial invasion
were observed as one – HSIL. Atypical squamous cell
(ASC) diagnosis comprised three diagnoses: atypical squa-
mous cells – undefined significance, atypical squamous
cells – heavy squamous intraepithelial lesion (HSIL) can
not be excluded and atypical squamous cells – invasive le-
sion can not be excluded. In data processing of glandular
epithelium lesions, atypical glandular cell (AGC) group
was observed as a whole, although Croatian modifica-
tion9 of Bethesda classification recognises three catego-
ries in this group – cases of probable reactive, intra-
epithelial or invasive lesions. AGC group and adeno-
carcinoma were divided according to origin of colum- nar
cells into endocervical, endometrial, extrauterine and
undefined origin.
Abnormal findings were divided into three groups:
ones where abnormal cells were found only in vaginal
smear (V), ones where abnormal cells were found in vagi-
nal and in at least one other smear (V+) and ones where
abnormal cells were not found in vaginal smear (C/E).
These three groups were analysed in respect to cytologi-
cal differential diagnosis and age of participants.
It was determined how many women could existing
cytological team additionally include in the screening, if
vaginal smear should be included in Pap test only after
50 years of age. Significance of difference was tested at
95% level10.
Results
Out of 245,048 examined smears, 12,639 (5.2%) were
abnormal. Exclusively in vaginal smear, abnormal cells
were found in 870 smears, which make 6.9% of all abnor-
mal results (i.e. 0.35% of all results). In combination of
vaginal smear and one other smear, abnormal cells were
found in 3,170 (25.1%) smears, and in 8,599 samples
(68%) abnormal cells were not found in vaginal smear
(Table 1).
Exclusively by vaginal smear it was discovered 7.2%
of squamous lesions (14.2% of ASC, 7.4% of LSIL, 2.7% of
HSIL and 1.7% of invasive squamous carcinoma), while
in 66.2% of lesions abnormal cells were not found in vagi-
nal smear (65.4% of ASC, 70.3% of LSIL, 57.9% of HSIL
and 7.8% of invasive squamous carcinoma). In 26.6% of
lesions abnormal cells were found both in vaginal and
cervical/endocervical smears (Table 2).
Exclusively by vaginal smear it was discovered 4.2%
of glandular lesions (3.9% of AGC and 6.3% of adenocar-
cinoma), while in 85.0% of lesions abnormal cells were
not found in vaginal smear (87.6% of AGC, 56.3% of AIS
V. Mili~i}-Juhas et al.: Pap Test – With or Without Vaginal Smear?, Coll. Antropol. 34 (2010) 1: 69–74
70
TABLE 1







819 3014 7526 11359
7.2% 26.5% 66.3% 100%
Glandular cell lesions
51 132 1036 1219
4.2% 10.8% 85% 100%
Squamous + Glandular cell lesions
0 24 37 61
0% 39.3% 60.7% 100%
Total
870 3170 8599 12639
6.9% 25.1% 68% 100%
V – vaginal smear, V+ – vaginal and at least one other smear, C/E – cervical and/or endocervical smear
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213 307 981 1501
14.2% 20.5% 65.4% 100%
26% 10.1% 13% 13.1%
LSIL
535 1622 5097 7254
7.4% 22.4% 70.3% 100%
65.2% 53.4% 67.4% 63.5%
HSIL
70 1003 1477 2550
2.7% 39.3% 57.9% 100%
8.5% 33% 19.5% 22.3%
Squamous cell carcinoma
2 104 9 115
1.7% 90.4% 7.8% 100%
0.2% 3.4% 0.1% 1%
Total
820 3036 7564 11420
7.2% 26.6% 66.2% 100%
100% 100% 100% 100%
V – vaginal smear, V+ – vaginal and at least one other smear, C/E – cervical and/or endocervical smear, ASC – abnormal squamous
cells, LSIL – low risk squamous intraepithelial lesion, HSIL – high risk squamous intraepithelial lesion
TABLE 3






28 57 984 1069
2.6% 5.3% 92% 100%
Endometrial
18 39 59 116
15.5% 33.6% 50.9% 100%
Undefined origin
1 5 8 14
7.1% 35.7% 57.1% 100%
Extrauterine
0 1 0 1
0% 100% 0% 100%
Total
47 102 1051 1200
3.9% 8.5% 87.6% 100%
AIS Endocervical
0 7 9 16
0% 43.8% 56.3% 100%
Adenocarcinoma
Endocervical
0 13 3 16
0% 81.3% 18.8% 100%
Endometrial
3 21 5 29
10.3% 72.4% 17.2% 100%
Undefined origin
1 12 4 17
5.9% 70.6% 23.5% 100%
Extrauterine
0 1 1 2
0% 50% 50% 100%
Total
4 47 13 64
6.3% 73.4% 20.3% 100%
V – vaginal smear, V+ – vaginal and at least one other smear, C/E – cervical and/or endocervical smear
and 20.3% of adenocarcinoma). In 10.8% of lesions ab-
normal cells were found both in vaginal and cervical/en-
docervical smears. Out of 6.3% of adenocarcinoma diag-
nosed exclusively by vaginal smear, 75% was endometrial
adenocarcinoma. However, out of all endometrial adeno-
carcinoma, exclusively by vaginal smear was diagnosed
only 10.3% (Tables 1 and 3).
Medium age of participants with squamous cell carci-
noma was 59,6 years, and of ones with adenocarcinoma it
was 66.6 years. There was neither one participant under
50 years of age with invasive squamous carcinoma or
adenocarcinoma that were diagnosed exclusively by vagi-
nal smear, while squamous cell carcinoma was diagnosed
exclusively by vaginal smear in 2.3%, and adenocar-
cinoma in 7.3% of participants over 50 years of age (Ta-
ble 4).
Dividing participants in two groups, regardless of
grade and type of lesion (squamous or glandular), exclu-
sively by vaginal smear was diagnosed 6.6% of lesions in
participants under 50 years of age, and 8.9% of lesions in
participants over 50 years of age (Table 5). There was
statistically significant difference in finding of abnormal
cells by vaginal smear among participants under and
over 50 years of age (z=–3.629, p=1.42*10–4).
Discussion and Conclusion
Value of vaginal sample as a part of conventional Pap test
is best illustrated by the type of lesion and the age in which
abnormal cells are found exclusively in vaginal smear.
In 6.9% of cytologically diagnosed lesions abnormal
cells were found exclusively in vaginal smear. As for
squamous cell lesions, 91.2% were mild lesions (ASC and
LSIL) (Table 2), which in respect to their biological be-
haviour have high probability of spontaneous regression
and/or possibility of later detection. As for invasive squa-
mous cell carcinoma, abnormal cells were found exclu-
sively in vaginal smear in 1.7% of women, but they were
all over 50 years of age. As for cytological diagnosis HSIL,
abnormal cells were found exclusively in vaginal smear
in 2.7% of women, and those lesions would not have been
discovered if vaginal smear had been excluded. However,
possibility of incorrect sampling of vaginal smear, where
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Under 50 years of age
0 22 6 28
0% 78.6% 21.4% 100%
Over 50 years of age
2 82 3 87
2.3% 94.3% 3.4% 100%
Total
2 104 9 115
1.7% 90.4% 7.8% 100%
Adenocarcinoma
Under 50 years of age
0 3 6 9
0% 33.3% 6.67% 100%
Over 50 years of age
4 39 12 55
7.3% 70.9% 21.8% 100%
Total
4 42 18 64
6.3% 65.6% 28.1% 100%
V – vaginal smear, V+ – vaginal and at least one other smear, C/E – cervical and/or endocervical smear
TABLE 5





Under 50 years of age
711 2673 7468 10852
6.6% 24.6% 68.8% 100%
Over 50 years of age
159 497 1131 1787
8.9% 27.8% 63.3% 100%
Total
870 3170 8599 12639
6.9% 25.1% 68% 100%
V – vaginal smear, V+ – vaginal and at least one other smear, C/E – cervical and/or endocervical smear
in one act a smear of posterior fornix and exocervix has
been done, can not be excluded.
Exclusively by vaginal smear has been detected over-
all 4.2% of glandular lesions (3.9% of AGC and 6.3% of
adenocarcinoma), while in 85.0% of lesions abnormal
cells were not found in vaginal smear. Since neither one
adenocarcinoma of endocervical origin nor adenocarcino-
ma in situ (AIS) was detected in vaginal smear, vaginal
smear has a role in detecting glandular epithelium le-
sions of endometrial origin. Out of all endometrial carci-
noma that were detected by Pap test, abnormal cells
were found exclusively in vaginal smear in 10.3% of
them, and since average age of participants with endo-
metrial carcinoma in our study was almost 67 (none of
the participants was under 50 years of age), if we should
not had taken vaginal smear to women under 50 years of
age, we would not have missed neither one endometrial
carcinoma.
Richart and Vaillant already determined that for wo-
men in reproductive age that have extremely low preva-
lence of endometrial carcinoma and high prevalence of
cervical neoplasia samples should be taken by techniques
that provide direct samples from cervix11.
Similar results obtained Pajtler et al.12,13, who also
pointed out clinical and economic unjustifiability of tak-
ing vaginal smears to women under 50 years of age.
From all said can be concluded that taking vaginal
smear along with cervical and endocervical smears as a
part of primary screening for cervical carcinoma and its
precursors to women under 50 years of age is not justifi-
able, since vaginal smear only has a role in detection of
endometrial carcinoma that are extremely rare in youn-
ger age groups.
In respect to age structure, 75.4% of examined popu-
lation was under, and 24.6% was over 50 years of age. If
vaginal smear should be taken only to women over 50
years of age, then to 185,109 women only CE smear
would be taken, and CVE smear would be taken to
60,299 women. At the same time and with the same staff
additional 92,554 CE smears (37.7%) to women under 50
years of age, or 61,703 VCE smears (25.1%) to women
over 50 years of age could be examined without signifi-
cant screening quality reduction. Our cytotechnologists
examine 45 smears daily during 7.5 working hours. Con-
sidering the age structure of our patients, they would
daily spend 112 minutes less for the same amount of
samples. Average time of waiting for Pap test results in
Croatia is 25 days, and the longest is 90 days. Therefore,
exclusion of vaginal smear in patients under 50 years of
age would reduce average time of waiting for Pap test re-
sults to 18.8 days, and the longest time of waiting to 67.7
days.
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PAPA TEST – SA ILI BEZ VAGINALNOG RAZMAZA?
S A @ E T A K
Cilj ove studije bio je procijeniti medicinsku i ekonomsku opravdanost uzimanja vaginalnog razmaza u sklopu pri-
marnog probira cervikalnog karcinoma i njegovih prekursora. U studiju je uklju~eno 245.408 ispitanica ~iji su VCE
(vaginalni, cervikalni, endocervikalni) razmazi bili pregledani na Odjelu za klini~ku citologiju Klini~kog bolni~kog cen-
tra Osijek od 2003. do 2008. godine. Abnormalnih je nalaza bilo 12.639 (5,2%), a podijeljeni su u tri skupine: abnor-
malne stanice na|ene samo u vaginalnom razmazu (V), abnormalne stanice na|ene u vaginalnom i bar u jo{ jednom
razmazu (V+) i abnormalne stanice nisu na|ene u vaginalnom razmazu (C/E). Te su tri skupine analizirane u odnosu
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na citolo{ku diferencijalnu dijagnozu i `ivotnu dob ispitanica. Procijenjeno je koliko bi se `ena moglo dodatno obuhva-
titi probirom ukoliko bi se vaginalni razmaz uklju~io u PAPA test tek nakon pedesete godine `ivota. U 6,9% citolo{ki
dijagnosticiranih lezija abnormalne su stanice na|ene isklju~ivo u vaginalnim razmazima (0,35% svih nalaza). Kod
lezija plo~astog epitela u 91,2% slu~ajeva radilo se o lak{im lezijama (ASC i LSIL). Invazivni plo~asti karcinom isklju-
~ivo vaginalnim razmazom nije dijagnosticiran niti u jedne `ene mla|e od 50 godina, dok je u `ena starijih od 50 godina
dijagnosticiran u 2,3% slu~ajeva. Isklju~ivo vaginalnim razmazom otkriveno je 3,9% svih AGC i 6,3% adenokarcinoma,
dok kod 85,0% lezija `ljezdanog epitela abnormalne stanice nisu na|ene u vaginalnim razmazima. Dvije tre}ine adeno-
karcinoma dijagnosticiranih isklju~ivo vaginalnim razmazom ~ini adenokarcinom endometrija, no to je samo 10,3%
svih PAPA testom dijagnosticiranih endometralnih karcinoma. Iz navedenih se rezultata mo`e zaklju~iti da `enama
mla|im od pedeset godina nema opravdanja uz cervikalni i endocervikalni uzeti i vaginalni razmaz u sklopu primarnog
probira cervikalnog karcinoma i njegovih prekursora, budu}i da vaginalni razmaz ima ulogu jedino u detekciji endo-
metralnih karcinoma koji su u mla|im dobnim skupinama izuzetno rijetki. Ukoliko bi se vaginalni razmaz uzimao
samo `enama starijim od 50 godina moglo bi se dodatno pregledati jo{ 37,7% `ena mla|ih od 50 godina, ili 25,1% `ena
starijih od 50 godina.
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